ArticleNature biotechnology2012
Interchangeability, immunogenicity and biosimilars.
Article in Nature biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Annals of the rheumatic diseases · 2017Trial
- On the achievable consistency of glycan distribution in biomanufacturing of therapeutic mAbs.NPJ advanced manufacturing · 2026Article
- A Deletion Variant of Human Factor VIII Displaying Low Immunogenicity in a Murine Model of Hemophilia A.International journal of molecular sciences · 2025Article
- Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.Pharmaceutics · 2022Review
- Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2020Article
- The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease.American journal of hematology · 2020Review
- Article
- Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Rheumatology (Oxford, England) · 2017Review
- Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.Immunologic research · 2017Observational
- Biosimilars in IBD: from theory to practice.Nature reviews. Gastroenterology & hepatology · 2017Review
- Monitoring Quality of Biotherapeutic Products Using Multivariate Data Analysis.The AAPS journal · 2016Review
- Assessing the Immunogenicity of Biopharmaceuticals.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2016Review
- Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.Frontiers in pharmacology · 2016Review
- Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.Journal of immunology research · 2016Review
- [Regulatory aspects of biosimilars. Myths and facts].Zeitschrift fur Rheumatologie · 2015Article
- Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.Clinical and experimental immunology · 2015Review
- The constrained prescription, interchangeability and substitution of biosimilars.Nature biotechnology · 2015Article
- Regulatory and clinical considerations for biosimilar oncology drugs.The Lancet. Oncology · 2014Review
- A review of approaches for the management of specialty pharmaceuticals in the United States.PharmacoEconomics · 2014Review
- Statistical and regulatory considerations in assessments of interchangeability of biological drug products.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23222784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.